GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer prevention through vaccination. GSK is investing up to £50 ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and ...

A new partnership between the University of Oxford and GSK aims to develop vaccines against cancer before develop ...

Oxford University and pharmaceutical giant GSK are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target cells at ...

Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

Oxford University is hoping to create a vaccine to stop the disease 20 years before it develops, as part of a joint project ...

A new cancer vaccine that ‘stops disease before you get it’ is being created by pharmaceutical giant GSK and the University ...

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...